share_log

力生制药(002393.SZ):药品吲达帕胺缓释片通过上市许可申请

Tianjin Lisheng Pharmaceutical (002393.SZ): Pharmaceutical Indapamide sustained-release tablets have been approved for marketing.

Zhitong Finance ·  Jul 2 03:47

Tianjin Lisheng Pharmaceutical (002393.SZ) announced that the company has received a "Drug Registration Certificate" (Batch No.: 2024S01229) issued by the National Medical Products Administration for the slow release tablet of Indapamide...

Lisheng Pharmaceutical (002393.SZ) announced that the company has received a "Drug Registration Certificate" (Batch No.: 2024S01229) issued by the National Medical Products Administration for the 1.5mg slow release tablet of Indapamide, which has been granted permission for sale. Indapamide is used to treat primary hypertension in adults.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment